| scholarly article | Q13442814 |
| P50 | author | Jules Dienstag | Q69897087 |
| Adrian M. Di Bisceglie | Q87445433 | ||
| P2093 | author name string | Leonard B Seeff | |
| Herbert L Bonkovsky | |||
| Gregory T Everson | |||
| William M Lee | |||
| Anna S F Lok | |||
| Marc G Ghany | |||
| Mitchell L Shiffman | |||
| HALT-C Trial Group | |||
| Jeffrey A Kahn | |||
| Chihiro Morishima | |||
| Deepa Naishadham | |||
| John C Hoefs | |||
| P2860 | cites work | Estimating future hepatitis C morbidity, mortality, and costs in the United States | Q73073538 |
| Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection | Q27860901 | ||
| Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial | Q27860949 | ||
| Epidemiology of hepatitis C | Q28249543 | ||
| Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose | Q29547886 | ||
| Histological grading and staging of chronic hepatitis | Q29619625 | ||
| The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 | Q29619974 | ||
| The prevalence of hepatitis C virus infection in the United States, 1988 through 1994 | Q29620136 | ||
| Diagnosis, management, and treatment of hepatitis C | Q29620656 | ||
| Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome | Q29620780 | ||
| A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation | Q33342063 | ||
| The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States | Q33892586 | ||
| The natural history of hepatitis C. | Q35877892 | ||
| Hepatocellular carcinoma: recent trends in the United States | Q35929212 | ||
| Management of cirrhosis due to chronic hepatitis C. | Q36074832 | ||
| Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: A National Heart, Lung, and Blood Institute collaborative study | Q38462606 | ||
| Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy | Q42993823 | ||
| Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. | Q43040369 | ||
| Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment | Q44901526 | ||
| Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. | Q46573661 | ||
| Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. | Q47678268 | ||
| Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. | Q50580484 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hepatitis C | Q154869 |
| chronic hepatitis | Q62019625 | ||
| chronic hepatitis C | Q55779873 | ||
| P304 | page(s) | 1675-1684 | |
| P577 | publication date | 2006-12-01 | |
| P1433 | published in | Hepatology | Q15724398 |
| P1476 | title | Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial | |
| P478 | volume | 44 |
| Q33906899 | A mathematical model of hepatitis C virus dynamics in patients with high baseline viral loads or advanced liver disease |
| Q30413350 | A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation |
| Q33395398 | A retrospective cohort study of partial splenic embolization for antiviral therapy in chronic hepatitis C with thrombocytopenia |
| Q38161848 | After the cure: management of HCV after achievement of SVR. |
| Q36080110 | An Open-Label Trial of 12-Week Simeprevir plus Peginterferon/Ribavirin (PR) in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 1 (GT1). |
| Q41359138 | Antiviral treatment in patients with hepatitis C virus-related cirrhosis awaiting liver transplantation |
| Q42241367 | Characterisation of the cytokine milieu associated with the up-regulation of IL-6 and suppressor of cytokine 3 in chronic hepatitis C treatment non-responders |
| Q47644014 | Direct-Acting Antiviral Sustained Virologic Response: Impact on Mortality in Patients without Advanced Liver Disease |
| Q42202021 | Effect of prolonged administration of pegylated interferon/ribavirin therapy in genotypes 2a and 2b: propensity score-matched analysis |
| Q24604495 | Exploitation of differential homeostatic proliferation of T-cell subsets following chemotherapy to enhance the efficacy of vaccine-mediated antitumor responses |
| Q43988022 | Factors responsible for the discrepancy between IL28B polymorphism prediction and the viral response to peginterferon plus ribavirin therapy in Japanese chronic hepatitis C patients |
| Q50559457 | Gender influence on treatment of chronic hepatitis C genotype 1. |
| Q43040102 | Genotype rs8099917 near the IL28B gene and amino acid substitution at position 70 in the core region of the hepatitis C virus are determinants of serum apolipoprotein B-100 concentration in chronic hepatitis C. |
| Q37060801 | Hepatitis C Viral Kinetics in Special Populations |
| Q50568778 | Hepatitis C: current options for nonresponders to peginterferon and ribavirin. |
| Q37984653 | Hepatocellular carcinoma: towards personalized medicine. |
| Q42213969 | High post-transplant virological response in hepatitis C virus infected patients treated with pretransplant protease inhibitor-based triple therapy |
| Q39450438 | Impact of FokI (rs10735810) and BsmI (rs1544410) on Treatment of Chronic HCV Patients With Genotype 4. |
| Q36334385 | Impact of antiviral therapy on hepatocellular carcinoma and mortality in patients with chronic hepatitis C: systematic review and meta-analysis. |
| Q43037449 | Impact of disease severity on outcome of antiviral therapy in treatment-naïve patients with chronic hepatitis C. |
| Q26782017 | Impact of new treatment options for hepatitis C virus infection in liver transplantation |
| Q42255702 | Impaired thymic output in patients with chronic hepatitis C virus infection. |
| Q37278723 | Increased sialylation of site specific O-glycoforms of hemopexin in liver disease. |
| Q33390478 | Individualisation of antiviral therapy for chronic hepatitis C. |
| Q37654502 | Individualization of chronic hepatitis C treatment according to the host characteristics |
| Q43033729 | Influence of HCV genotype 1 subtypes on the virus response to PEG interferon alpha-2a plus ribavirin therapy |
| Q37108845 | Innate immunity and alcoholic liver fibrosis |
| Q36104827 | Mallory-Denk bodies are associated with outcomes and histologic features in patients with chronic hepatitis C. |
| Q36849347 | Management of chronic hepatitis C: consensus guidelines |
| Q28081250 | Management of hepatitis C infection before and after liver transplantation |
| Q27490409 | Managing chronic hepatitis C in the difficult-to-treat patient |
| Q33421239 | Non-cirrhotic thrombocytopenic patients with hepatitis C virus: Characteristics and outcome of antiviral therapy |
| Q36546657 | Non-invasive prediction of hepatic fibrosis in patients with chronic HCV based on the routine pre-treatment workup. |
| Q37032551 | Nonresponse to treatment for hepatitis C: current management strategies |
| Q42656554 | Peginterferon α-2a plus ribavirin in Latino and Non-Latino Whites with HCV genotype 1: Histologic outcomes and tolerability from the LATINO Study |
| Q37189032 | Peginterferon-alpha-2a (40 kD) plus ribavirin: a review of its use in the management of chronic hepatitis C mono-infection |
| Q45393757 | Pegylated interferon and ribavirin combination therapy for chronic hepatitis C virus infection in patients with Child-Pugh Class A liver cirrhosis. |
| Q37627878 | Pharmacotherapy of chronic hepatitis C virus infection - the IDEAL trial: '2b or not 2b (= 2a), that is the question'. |
| Q35862839 | Post-transplant survival is improved for hepatitis C recipients who are RNA negative at time of liver transplantation |
| Q34409039 | Predicting the probable outcome of treatment in HCV patients |
| Q42988539 | Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study |
| Q34114361 | Predictors of response to 24-week telaprevir-based triple therapy for treatment-naïve genotype 1b chronic hepatitis C patients. |
| Q33694159 | Processes to manage analyses and publications in a phase III multicenter randomized clinical trial |
| Q36281852 | Promotion of Cancer Stem-Like Cell Properties in Hepatitis C Virus-Infected Hepatocytes |
| Q37156704 | Quantitative tests of liver function measure hepatic improvement after sustained virological response: results from the HALT-C trial |
| Q42981703 | Quercetin: bioflavonoids as part of interferon-free hepatitis C therapy? |
| Q36066514 | Randomized trial comparing dose reduction and growth factor supplementation for management of hematological side effects in HIV/hepatitis C virus patients receiving pegylated-interferon and ribavirin |
| Q54203070 | Regulation of interferon signaling and HCV‑RNA replication by extracellular matrix. |
| Q42983977 | Response to pegylated interferon plus ribavirin among HIV/hepatitis C virus-coinfected patients with compensated liver cirrhosis |
| Q36968144 | Retreatment of chronic hepatitis C in previous non-responders and relapsers |
| Q42988052 | Role of IL-28B and inosine triphosphatase polymorphisms in efficacy and safety of Peg-Interferon and ribavirin in chronic hepatitis C compensated cirrhosis with and without oesophageal varices. |
| Q37905905 | Role of the nurse practitioner in the management of patients with chronic hepatitis C. |
| Q37155233 | SRM targeted proteomics in search for biomarkers of HCV-induced progression of fibrosis to cirrhosis in HALT-C patients |
| Q43046716 | Serum PAI-1 is a novel predictor for response to pegylated interferon-α-2b plus ribavirin therapy in chronic hepatitis C virus infection |
| Q46851801 | Significance of liver stiffness measurement by acoustic radiation force impulse (ARFI) among hepatitis C patients |
| Q38458110 | Sorting out cirrhosis: mechanisms of non-response to hepatitis C therapy |
| Q41535486 | Successful anti-viral treatment improves survival of patients with advanced liver disease due to chronic hepatitis C. |
| Q34172595 | Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more |
| Q81446455 | The accuracy of sonography in predicting steatosis and fibrosis in chronic hepatitis C |
| Q34996746 | The practical management of treatment failure in chronic hepatitis C: a summary of current research and management options for refractory patients |
| Q38562544 | Therapy of Delta Hepatitis |
| Q33916357 | Treatment options for HCV nonresponders and relapse patients |
| Q42208113 | Value of Egy-Score in diagnosis of significant, advanced hepatic fibrosis and cirrhosis compared to aspartate aminotransferase-to-platelet ratio index, FIB-4 and Forns' index in chronic hepatitis C virus |
| Q43047895 | Very low viral load (VLVL) relapse following treatment of naïve patients with chronic hepatitis C. |
| Q42287249 | Very-Low-Dose Pegylated Interferon α2a Plus Ribavirin Therapy for Advanced Liver Cirrhosis Type C: A Possible Therapeutic Alternative without Splenic Intervention |
Search more.